Uploaded image for project: 'eCQM Issue Tracker'
  1. eCQM Issue Tracker
  2. CQM-6663

PCV20 not included in eCQM Update for CMS117v12

XMLWordPrintable

    • Icon: EC eCQMs EC eCQMs
    • Resolution: Answered
    • Icon: Moderate Moderate
    • None
    • None
    • Esperanza Health Centers
    • Hide
      Thank you for your inquiry about CMS117, Childhood Immunization Status. Published versions of the measures in the Quality Payment Program cannot be changed after publication. We anticipate to align with the current ACIP guidelines during our current annual update cycle.
      For the performance year 2023 and 2024, implementers may map the pneumococcal conjugate vaccine 20 valent to CVX code 109 or CVX 152 in the 'Pneumococcal Conjugate Vaccine' OID: 2.16.840.1.113883.3.464.1003.196.12.1221 value set. If mapping is done, you should maintain documentation in case of a CMS audit.
      Show
      Thank you for your inquiry about CMS117, Childhood Immunization Status. Published versions of the measures in the Quality Payment Program cannot be changed after publication. We anticipate to align with the current ACIP guidelines during our current annual update cycle. For the performance year 2023 and 2024, implementers may map the pneumococcal conjugate vaccine 20 valent to CVX code 109 or CVX 152 in the 'Pneumococcal Conjugate Vaccine' OID: 2.16.840.1.113883.3.464.1003.196.12.1221 value set. If mapping is done, you should maintain documentation in case of a CMS audit.
    • CMS0117v12
    • CMS0117v11
    • Substantial impact on our performance rate on the measure

      Per the Updated Recommendations of the Advisory Committee on Immunization Practices published July 2023, our health center (and VFC program) has transitioned to the 20-valent pneumococcal conjugate vaccine (PCV20) for children. However, PCV20 is not included in the eCQM Update 2023-05-04 version of the Pneumococcal Conjugate Vaccine value set used for CMS117v12; it is only included in the latest value set.

      As a Federally Qualified Health Center, we are required to report CMS117 as part of the Uniform Data System. If held strictly to CMS117v12 and eCQM Update 2023-05-04 for this value set, we will not be able to satisfy the measure in the 2024 Performance Period for any children who received any number of PCV20 doses for their 4-dose series (a substantial impact). Note that this also poses a problem for Performance Period 2023, though the impact is much smaller due to most pneumococcal vaccine series being completed for eligible patients prior to the updated recommendations for PCV20.

            edave Mathematica EC eCQM Team
            samuelmross Sam Ross
            Votes:
            0 Vote for this issue
            Watchers:
            3 Start watching this issue

              Created:
              Updated:
              Resolved:
              Solution Posted On: